Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Turn Therapeutics Inc.NASDAQ: TTRX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity of $6.12M in Q1 FY2026
Q1 FY2026 total equity was $6.12M.
Context
- Total equity amounted to 32.8% of total assets at the end of Q1 FY2026.
- Total equity increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 4.69M USD
- Year-over-year change
- +2741.4%
- 2-year CAGR
- +639.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.69M | +2741.4% |
| FY2024 | 2024-12-31 | (177.43K) | -306.9% |
| FY2023 | 2023-12-31 | 85.77K | — |
Total Equity vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 total equity of $6.12M is the 6th highest of the 9 companies compared; the peer median is $18.21M.
- Total equity amounts to 32.8% of total assets for TTRX, versus a peer median of 85.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $241.48M | -22.4% | -16.6% | 88.7% | |
| Mar 2026 | $167.62M | +95.5% | +101.8% | 96.7% | |
| Mar 2026 | $29.91M | +143.8% | -5.2% | 82.8% | |
| Mar 2026 | $23.19M | +135.3% | +19.4% | 78.1% | |
| Apr 2026 | $13.22M | -11.3% | -20.9% | 89.0% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $6.12M | — | — | 32.8% |
| Mar 2026 | $5.27M | +301.6% | -48.6% | 50.2% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$45.84M | -1003.5% | -30.8% | 68.6% |
| Mar 2026 | -$227.98M | +29.3% | — | 122.3% | |
| Peer median (excluding TTRX) | $18.21M | +62.4% | -16.6% | 85.8% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.